Brand Names/MOA/Indications

Question 1

alectinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 1

(1) Alecensa
(2) ALK and RET TKI
(3) ALK positive NSCLC

Question 2

thalidomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 2

(1) Thalomid
(2) Angiogenesis inhibitor
(3) Multple Myeloma

Question 3

olaparib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 4

Answer 3

(1) Lynparza
(2) PARP Inhibitor
(3) Ovarian, breast, pancreatic, and prostate cancer

Question 4

palbociclib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 4

(1) Ibrance
(2) CDK 4/6 Inhibitor
(3) HR+/HER2- advanced/metastatic breast cancer

Question 5

cobimetinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 5

(1) Cotellic
(2) MEK Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600 E or V600K mutation (in combination with vemurafenib)

Question 6

ibrutinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 5

Answer 6

(1) Imbruvica
(2) Bruton tyrosine kinase (BTK) inhibitor
(3) CLL/SLL, MCL, WM, chronic graft vs host disease, marginal zone lymphoma

Question 7

imatinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

Answer 7

(1) Gleevec
(2) BCR-ABL and cKIT TKI
(3) CML and GIST

Question 8

ribociclib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 8

(1) Kisqali
(2) CDK 4/6 Inhibitor
(3) HR+/HER2- advanced/metastatic breast cancer

Question 9

erlotinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 9

(1) Tarceva
(2) Early generation EGFR TKI
(3) Lung cancer

Question 10

neratinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 10

(1) Nerlynx
(2) EFGR, HER2, and HER 3/4 TKI
(3) HER2+ breast cancer post adjuvant HER2 directed therapy

Question 11

cabozantinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

Answer 11

(1) Cabometyx
(2) Multi-TKI inc. VEGF
(3) Renal cell and hepatocellular carcinoma

Question 12

temozolomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 12

(1) Temodar
(2) Cytotoxic agent: alkylating agent
(3) Glioblastoma

Question 13

niraparib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 3

Answer 13

(1) Zejula
(2) PARP Inhibitor
(3) Maintenance treatment in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy

Question 14

trametinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 14

(1) Mekinist
(2) MEK Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600E mutation (in combination with dabrafenib)

Question 15

gefitinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 15

(1) Iressa
(2) Early generation EGFR TKI
(3) Lung cancer

Question 16

rucaparib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications - 2

Answer 16

(1) Rubraca
(2) PARP Inhibitor
(3) Ovarian and prosate cancer

Question 17

capecitabine:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 17

(1) Xeloda
(2) Cytotoxic agent: antimetabolite
(3) Adjuvant therapy for colon cancer, metastatic colon cancer, rectal cancer, breast cancer

Question 18

afatinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 18

(1) Gilotrif
(2) Early generation EGFR TKI
(3) Lung cancer

Question 19

lapatinib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 19

(1) Tykerb
(2) EGFR and HER2 TKI
(3) HER+ advanced or metastatic breast cancer in combination with:
a) capecitabine in patients who’ve previously
received an anthracycline, taxane, and trastuzumab
b) letrozole in patients eligible for hormonal therapy

Question 20

dabrafenib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 20

(1) Tafinlar
2) BRAF Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600E mutation (in combination with trametinib)

Question 21

enzalutamide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 21

(1) Xtandi
(2) Androgen receptor antagonist
(3) Non-metastatic and metastatic castration resistant prostate cancer

Question 22

apalutamide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 22

(1) Erleada
(2) Androgen receptor antagonist
(3) Non-metastatic castration resistant prostate cancer

Question 23

vemurafenib:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 23

(1) Zelboraf
(2) BRAF Inhibitor
(3) Unresectable or metastatic melanoma with BRAF V600E mutation

Question 24

pomalidomide:
(1) Brand Name
(2) Drug Class/MOA
(3) Main Indications

Answer 24

(1) Pomalyst
(2) Angiogenesis inhibitor
(3) Multple Myeloma

Question 25

abiraterone: (1) Brand Name (2) Drug Class/MOA (3) Main Indications

Answer 25

(1) Zytiga (2) CYP17 inhibitor - essential enzyme in androgen production (3) metastatic, castrate-sensitive prostate cancer and metastatic, castrate-resistant prostate cancer

Question 26

pazopanib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications - 2

Answer 26

(1) Votrient (2) Multi-TKI inc. VEGF (3) RCC and soft tissue sarcoma

Question 27

venetoclax: (1) Brand Name (2) Drug Class/MOA (3) Main Indications - 2

Answer 27

(1) Venclexta (2) Selective small molecule inhibitor of the anti-apoptotic protein beta cell lymphoma-2 (BCL-2) (3) CLL and small lymphocitic leukemia

Question 28

osimertinib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications

Answer 28

(1) Tagrisso (2) EGFR TKI including T790M mutation (3) EFGR positive NSCLC q/ T790M mutation who have progressed on or after EGFR TKI therapy.

Question 29

abemaciclib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications

Answer 29

(1) Verzenio (2) CDK 4/6 Inhibitor (3) HR+/HER2- advanced/metastatic breast cancer

Question 30

ruxolitinib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications

Answer 30

(1) Jakafi (2) JAK1 & JAK2 inhibitor (3) myelofibrosis, polycythemia vera (if inadequate response to hydroxyurea), aGVHD

Question 31

lenalidomide: (1) Brand Name (2) Drug Class/MOA (3) Main Indications

Answer 31

(1) Revlimid (2) Angiogenesis inhibitor (3) Multple Myeloma

Question 32

sorafenib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications - 2

Answer 32

(1) Nexavar (2) Multi-TKI inc. VEGF (3) RCC, hepatocellular carcinoma

Question 33

crizotinib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications

Answer 33

(1) Xalkori (2) ALK Inhibitor (3) ALK positive NSCLC

Question 34

sunitinib: (1) Brand Name (2) Drug Class/MOA (3) Main Indications - 3

Answer 34

(1) Sutent (2) Multi-TKI inc. VEGF (3) RCC, GIST, pancreatic neuroendocrine tumors